Approval · Notice of Compliance 15947 · 2014
ACT MEMANTINE: Notice of Compliance 15947
Issued August 14, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 15947
- Date
- August 14, 2014
- Company
- Actavis Pharma CompanyToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Manufacturer and product name change
- Therapeutic class
- N-methyl D-aspartate (nmda) receptor antagonist
- Canadian reference product
- EBIXA (Lundbeck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT MEMANTINE | 02324059 | Approved |
| ACT MEMANTINE | 02324067 | Marketed |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 5 MG per TAB
- MEMANTINE HYDROCHLORIDE 10 MG per TAB